380 related articles for article (PubMed ID: 35281349)
1. The dawn of precision medicine in diffuse-type gastric cancer.
Ooki A; Yamaguchi K
Ther Adv Med Oncol; 2022; 14():17588359221083049. PubMed ID: 35281349
[TBL] [Abstract][Full Text] [Related]
2. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
Ooki A; Yamaguchi K
Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
4. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.
Wang K; Li E; Busuttil RA; Kong JC; Pattison S; Sung JJY; Yu J; El-Omar EM; Simpson JA; Boussioutas A
Ther Adv Med Oncol; 2020; 12():1758835920930359. PubMed ID: 32754227
[TBL] [Abstract][Full Text] [Related]
5. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
6. Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?
Mathias-Machado MC; de Jesus VHF; Jácome A; Donadio MD; Aruquipa MPS; Fogacci J; Cunha RG; da Silva LM; Peixoto RD
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339430
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
8. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer.
Díaz Del Arco C; Estrada Muñoz L; Ortega Medina L; Molina Roldán E; Cerón Nieto MÁ; García Gómez de Las Heras S; Fernández Aceñero MJ
World J Gastrointest Oncol; 2022 Jun; 14(6):1162-1174. PubMed ID: 35949214
[TBL] [Abstract][Full Text] [Related]
11. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
12. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.
Gordon A; Johnston E; Lau DK; Starling N
Onco Targets Ther; 2022; 15():1183-1196. PubMed ID: 36238135
[TBL] [Abstract][Full Text] [Related]
13. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A; Brignola S; Riello E; Niero M; Murgioni S; Guido M; Nappo F; Businello G; Sbaraglia M; Bergamo F; Spolverato G; Pucciarelli S; Merigliano S; Pilati P; Cavallin F; Realdon S; Farinati F; Dei Tos AP; Zagonel V; Lonardi S; Loupakis F; Fassan M
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834447
[TBL] [Abstract][Full Text] [Related]
14. Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the
Teles SP; Oliveira P; Ferreira M; Carvalho J; Ferreira P; Oliveira C
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31881796
[TBL] [Abstract][Full Text] [Related]
15. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
16. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.
Grizzi G; Venetis K; Denaro N; Bonomi M; Celotti A; Pagkali A; Hahne JC; Tomasello G; Petrelli F; Fusco N; Ghidini M
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109309
[TBL] [Abstract][Full Text] [Related]
17. Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer.
Shirakihara T; Yamaguchi H; Kondo T; Yashiro M; Sakai R
Oncogene; 2022 Apr; 41(18):2587-2596. PubMed ID: 35338344
[TBL] [Abstract][Full Text] [Related]
18. Profiling Kinase Activities for Precision Oncology in Diffuse Gastric Cancer.
Singh S; Parthasarathi KTS; Bhat MY; Gopal C; Sharma J; Pandey A
OMICS; 2024 Feb; 28(2):76-89. PubMed ID: 38271566
[TBL] [Abstract][Full Text] [Related]
19. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
20. SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling.
Nagamura Y; Miyazaki M; Nagano Y; Tomiyama A; Ohki R; Yanagihara K; Sakai R; Yamaguchi H
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
